Technical Analysis for IFRX - InflaRx N.V.

Grade Last Price % Change Price Change
grade D 35.11 -10.20% -3.99
IFRX closed down 10.2 percent on Friday, May 24, 2019, on 2.29 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical IFRX trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Fell Below 200 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
Reversal New Lows Setup Bearish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
Multiple of Ten Bearish Other 0.00%
Outside Day Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%

Older signals for IFRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Medicine Biotechnology Biopharmaceutical Medical Specialties Immunology Antibodies Immune System Monoclonal Antibodies Inflammatory Diseases
Is IFRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 53.1
52 Week Low 20.31
Average Volume 242,801
200-Day Moving Average 35.6486
50-Day Moving Average 43.8454
20-Day Moving Average 41.984
10-Day Moving Average 39.729
Average True Range 2.9377
ADX 21.75
+DI 10.6549
-DI 25.8169
Chandelier Exit (Long, 3 ATRs ) 42.8169
Chandelier Exit (Short, 3 ATRs ) 42.1231
Upper Bollinger Band 47.7216
Lower Bollinger Band 36.2464
Percent B (%b) -0.1
BandWidth 27.332317
MACD Line -2.0162
MACD Signal Line -1.3022
MACD Histogram -0.714
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 49.63
Resistance 3 (R3) 50.64 46.82 47.21
Resistance 2 (R2) 46.82 43.12 46.31 46.40
Resistance 1 (R1) 40.96 40.83 39.05 39.95 45.60
Pivot Point 37.14 37.14 36.18 36.63 37.14
Support 1 (S1) 31.28 33.44 29.37 30.27 24.62
Support 2 (S2) 27.46 31.15 26.95 23.82
Support 3 (S3) 21.60 27.46 23.01
Support 4 (S4) 20.59